Pork Sales Intern

The AVA secures $150,000 Zoetis Foundation grant. The Australian Veterinary Association (AVA) has received a USD $150,000 grant from the Zoetis Foundation to expand its Cultivating Safe Teams program nationwide. The funding will support the AVA's goal of training every veterinary professional in Australia to identify and manage psychosocial risks in the workplace. More than 1,300 veterinary professionals have completed the training since it launched in 2023. Cultivating Safe Teams is the flagship program under the AVA's THRIVE wellbeing initiative, which targets psychological harm in veterinary workplaces. Dr Diana Barker, President of the AVA, said the grant would allow the organisation to broaden the program's reach. "Veterinary teams do extraordinary work under real pressure, and for too long the toll of that pressure has gone unaddressed. "This grant enables us to take a program that works and put it in front of every veterinary professional in the country." The program grew out of the AVA's 2021 Veterinary Stakeholder Wellness Survey, which found two in three veterinary professionals had experienced a mental health condition, and almost half said their work was harming their mental health. Cultivating Safe Teams runs as a one-hour awareness session built around evidence-based workplace psychological health and safety frameworks, designed to fit around busy clinic schedules. Among participants, 93 per cent rated the session useful and 94 per cent rated it relevant, while confidence in identifying psychosocial hazards rose by 60 per cent. Dr Barker explained that proactive management of psychosocial risk is now the law in every Australian jurisdiction, so there has never been a more important time to act. "This is about more than compliance. It is about building workplaces where people are safe, supported and want to stay, and that is good for our people, our patients and the future of the profession." The AVA is now expanding the program beyond awareness-raising with a new offering, CST ACTION, which trains workplace champions to run a validated risk assessment and design initiatives tailored to their own hazard profile. The offering includes coaching from organisational psychologists, self-paced modules and peer-to-peer learning. Expressions of interest for the 2027 program are open now on the AVA website. Jeannette Ferran Astorga, Executive Vice President of Corporate Affairs at Zoetis and President of the Zoetis Foundation, said the funding reflected the company's commitment to the sector. "The veterinary profession is foundational to animal health, and the professionals caring for animals deserve workplaces that protect their wellbeing. "We are proud to support the AVA in scaling a program that is already making a measurable difference to veterinary teams across Australia." Cultivating Safe Teams is delivered with support from the Zoetis Foundation, Crampton Consulting Group, Hill's Pet Nutrition and Troy.

Zoetis stands by guidance as pet-care weakness and competition pressure sales. September 18, 2026 Key points. * Zoetis maintained its revised guidance for operational revenue declining 3% to 1%, citing weaker U.S. pet-care demand, fewer veterinary visits and intensified competition in dermatology and parasiticides. * The company is using targeted, time-limited promotions to defend market share rather than broadly cutting prices. Apoquel retained about 87% U.S. share, while parasiticide share declined roughly 1% in the latest quarter. * Future growth opportunities include renal disease, oncology and livestock, with a potential renal treatment approval expected late next year and livestock revenue growing at a double-digit pace. * MarketBeat previews the top five stocks to own by October 1st. Zoetis NYSE: ZTS executives said the company remains confident in its previously issued guidance despite pressure in the U.S. companion-animal market, citing a weaker pet-care environment and intensified competition in dermatology and parasiticides. Speaking at a Morgan Stanley conference, CEO Kristin Peck said the company's revised operational revenue outlook of negative 3% to negative 1% reflects both industry conditions and company-specific competitive dynamics. Zoetis had previously forecast operational revenue growth of 2% to 5%. "For the first time, we saw a declining pet care market," Peck said, pointing to lower veterinary visits and affordability challenges for pet owners. She said parasiticides declined 6.7% industrywide, while demand has been stronger in diagnostic testing and products associated with specialty, urgent and critical care. Targeted promotions and competitive pressure. Peck characterized the company's current pricing pressure as cyclical rather than structural. Zoetis has not broadly reduced list prices for its key dermatology and parasiticide products, she said. Instead, the company has used targeted, time-limited promotions and discounts intended to win business from customers using competing products. "This isn't everybody, 10% discount for anyone who wants to buy," Peck said. "This is, you're buying my competitor's product today, we want to be your parasiticide of choice." The company began many of those targeted programs in the second quarter and made them more aggressive in the third quarter after initial promotions did not deliver the desired results. Peck said Zoetis will assess the programs each quarter and adjust their scope and intensity as needed. She said the company is pleased with the early performance of the actions, while noting that competition can prompt responses from rivals. Zoetis is seeking to protect market share, particularly in categories where it historically held dominant positions, while also using its broad product portfolio and pipeline to support relationships with veterinarians and corporate veterinary customers. Discover more Dividend Screener Tool Compare Investment Apps Jay Saccaro, Zoetis' recently appointed CFO and COO, said he was attracted to the company by its leadership position, commercial capabilities and innovation pipeline. After several weeks in the role, he said his initial observations have been "confirmatory," including the strength of the company's products and the engagement of its employees. Saccaro said the company's assumptions about market conditions are tracking as expected and that management remains confident in guidance. Zoetis plans to update investors in November. Parasiticides, dermatology and product pipeline. In parasiticides, Peck said Zoetis remains the U.S. market-share leader, with nearly twice the share of the next competitor. The company's share declined about 1% during the prior quarter, which she described as relatively stable amid competitive activity. Zoetis continues to see an opportunity to expand the parasiticide market by converting customers from single agents, collars and topical products to triple-combination products. International markets also remain a growth opportunity, Peck said, citing the recent launch of Simparica Trio in Brazil. In dermatology, Zoetis faces a third entrant competing against Apoquel. Peck said the company finished the quarter with approximately 87% U.S. share for Apoquel, while acknowledging that its historically high share will decline as competitors enter. Zoetis expects an approval for long-acting Cytopoint Plus in the U.S. by year-end and continues to promote Apoquel Chewable, Apoquel and Cytopoint as a differentiated portfolio. Peck said Apoquel's first loss of exclusivity is expected in 2032, excluding the chewable formulation. She also highlighted an estimated 16 million untreated dogs in the U.S. with dermatological conditions as an opportunity to expand treatment. Management expects the penetration of newly launched dermatology products to take roughly 18 months historically, though Peck said the pace could vary. Zoetis is watching both share movements and a potential recovery in the broader pet-care market to determine when promotional spending can normalize. Renal disease, oncology and livestock growth. Zoetis identified chronic kidney disease, oncology, cardiology, anxiety, diabetes and obesity as important pipeline opportunities. Peck said renal disease is the nearest-term and largest of those opportunities, describing an approximately $3 billion addressable market. The company has a renal product targeted for approval at the end of next year that is intended to slow disease progression, along with planned diagnostics, biomarkers and additional therapies. Peck said roughly 20% of dogs and 40% of cats develop renal or chronic kidney disease. Zoetis also has two oncology products in its pipeline, including one management believes could become a blockbuster product, defined by the company as one with potential annual sales of $1 billion. The company expects oncology therapies will need to be suitable for use by general veterinary practitioners, in addition to specialists. Meanwhile, livestock has produced double-digit growth this year, according to Peck. She attributed the strength partly to higher protein consumption in developed markets associated with GLP-1 medicines. Growth has extended across species, with fish and poultry the fastest-growing globally and continued strength in U.S. beef and dairy cattle. Zoetis has also reduced list prices for Cerenia and Convenia in response to generic competition, a structural pricing action distinct from its targeted promotions in dermatology and parasiticides. Peck said the company does not expect other large products to face generic competition before 2032. About Zoetis (NYSE:ZTS). Zoetis Inc is a global animal health company that develops, manufactures and commercializes medicines, vaccines, diagnostic products and related services for livestock and companion animals. Its offerings are used by veterinarians, livestock producers and pet owners to prevent and treat disease, improve animal health and support productivity. The company's product portfolio includes pharmaceuticals, vaccines, parasiticides, dermatology treatments, diagnostic tests and genetic services. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Zoetis, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zoetis wasn't on the list. While Zoetis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you'll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America. Continue following MarketBeat